UNTOLD Ovarian Cancer Unmet Needs Survey
Launched by MASONIC CANCER CENTER, UNIVERSITY OF MINNESOTA · Jul 8, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study, called the UNTOLD Ovarian Cancer Unmet Needs Survey, aims to better understand the ongoing concerns and needs of women living with ovarian cancer. The researchers want to hear directly from ovarian cancer survivors about their experiences after diagnosis, to learn what challenges they still face and what support they may need.
Women who have been diagnosed with ovarian cancer (including cancers of the ovaries, fallopian tubes, or the lining of the abdomen) and can read and write in English may be eligible to participate. If you join, you will complete a one-time survey sharing your experiences. Some participants may also be invited to take part in a follow-up interview to talk more about their journey. The study plans to recruit participants through cancer registries and ovarian cancer support groups to include a wide range of voices. This research is not yet open for enrollment but aims to help improve care and resources for women with ovarian cancer in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Ability to read and write in English
- • Diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube)
- Exclusion Criteria:
- • -
About Masonic Cancer Center, University Of Minnesota
The Masonic Cancer Center at the University of Minnesota is a leading institution dedicated to cancer research, treatment, and prevention. As a National Cancer Institute-designated Comprehensive Cancer Center, it integrates innovative research with clinical practice to enhance patient care and advance medical knowledge. The center fosters collaboration among scientists, clinicians, and educators, focusing on multidisciplinary approaches to tackle the complexities of cancer. Through its commitment to cutting-edge clinical trials, the Masonic Cancer Center aims to translate scientific discoveries into effective therapies, ultimately improving outcomes for cancer patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported